Journal
ANNALS OF ONCOLOGY
Volume 18, Issue 11, Pages 1828-1833Publisher
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdm332
Keywords
chemotherapy; hormone-refractory prostate cancer; overall survival; predictive factor; prostate-specific antigen doubling time
Categories
Ask authors/readers for more resources
Background: We evaluated the possible use of prostate-specific antigen doubling time (PSA-DT) before chemotherapy initiation as a surrogate marker of survival in hormone-refractory prostate cancer (HRPC) patients. Patients and methods: Data from 250 consecutive metastatic HRPC patients treated with chemotherapy between February 2000 and November 2006 were retrospectively analysed. At least three PSA assays were required within 3 months before chemotherapy. PSA-DT was calculated as In 2 divided by the slope of the log PSA line, and the difference between two log PSA levels was divided by the time interval. The primary endpoint was overall survival (OS). Survival rates according to PSA-DT were stratified on chemotherapy regimen. Multivariate Cox regression analysis was performed to isolate the impact of PSA-DT on OS, controlling for associate prognostic covariates. Results: Patients received clocetaxel-(82%) or mitoxantrone-based chemotherapy. The median PSA-DT was 45 days (range 4.7-1108 days). There were 174 deaths (70%). The median survival was 16.5 months (95% confidence interval [Cl] = 12.5-20.5) and 26.4 months (95% Cl = 20.3-32.4) for patients with a PSA-DT < 45 and >= 45 days, respectively. In the multivariate setting, the adjusted hazard ratio (HR) was 1.39 (95% Cl = 1.03-1.89; P = 0.04), stratified by chemotherapy regimen. Conclusion: A short PSA-DT before onset of chemotherapy in HRPC patients was associated with an increased risk of death. This could be useful as a stratification parameter in trials with new drugs in a metastatic setting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available